Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Syndax Pharmaceuticals is a biotechnology business based in the US. Syndax Pharmaceuticals shares (SNDX) are listed on the NASDAQ and all prices are listed in US Dollars. Syndax Pharmaceuticals employs 107 staff and has a trailing 12-month revenue of around $126.6 million.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $23.07 |
|---|---|
| 52-week range | $13.27 - $29.86 |
| 50-day moving average | $25.54 |
| 200-day moving average | $22.94 |
| Wall St. target price | $33.38 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.36 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $23.07 from 2023-03-21
| 1 week (2023-03-15) | 3.45% |
|---|---|
| 1 month (2023-02-22) | -9.17% |
| 3 months (2022-12-22) | -8.52% |
| 6 months (2022-09-22) | 1.14% |
| 1 year (2022-03-18) | 38.06% |
|---|---|
| 2 years (2021-03-22) | -5.02% |
| 3 years (2020-03-20) | 170.77% |
| 5 years (2018-03-22) | 59.21% |
| Revenue TTM | $126.6 million |
|---|---|
| Gross profit TTM | $139.7 million |
| Return on assets TTM | -20.03% |
| Return on equity TTM | -34.1% |
| Profit margin | 0% |
| Book value | $6.86 |
| Market capitalisation | $1.5 billion |
TTM: trailing 12 months
We're not expecting Syndax Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Syndax Pharmaceuticals's shares have ranged in value from as little as $13.27 up to $29.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Syndax Pharmaceuticals's is 1.0393. This would suggest that Syndax Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Syndax Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.